Biological Optimization Versus Standard Care in Post-POEM Achalasia Patients (BIO-POEM) (BIO-POEM 1)
Randomized Controlled Trial of Structured Biological Optimization Versus Standard Care With Embedded Prospective Registry in Post-POEM Achalasia Cardia Patients.
This study aims to evaluate whether a structured biological optimization program can improve reflux symptoms and overall recovery in patients with achalasia cardia who previously underwent Peroral Endoscopic Myotomy (POEM). Although POEM is highly effective for relieving swallowing difficulty, many patients develop gastroesophageal reflux disease (GERD) after the procedure and remain dependent on long-term acid suppressive medications such as proton pump inhibitors (PPIs).
The BIO-POEM study will compare structured biological optimization with standard post-POEM care in patients with objectively confirmed pathological reflux after POEM. The intervention includes reflux-oriented dietary counseling, micronutrient assessment and correction, Helicobacter pylori testing and eradication when indicated, lifestyle optimization, and structured review and tapering of PPI/PCAB therapy.
The study includes two components:
A randomized controlled trial enrolling post-POEM patients with objectively confirmed reflux.
A parallel prospective observational registry enrolling symptomatic post-POEM patients who are unable to undergo reflux testing or who remain symptomatic despite low acid exposure.
The primary objective is to determine whether structured biological optimization reduces GERD symptom burden at 12 months compared with standard care. Secondary objectives include evaluation of dyspepsia symptoms, nutritional recovery, quality of life, reduction in PPI dependence, and exploratory assessment of gut microbiome changes.
調査の概要
詳細な説明
This study aims to evaluate whether a structured biological optimization program can improve reflux symptoms and overall recovery in patients with achalasia cardia who previously underwent Peroral Endoscopic Myotomy (POEM). Although POEM is highly effective for relieving swallowing difficulty, many patients develop gastroesophageal reflux disease (GERD) after the procedure and remain dependent on long-term acid suppressive medications such as proton pump inhibitors (PPIs).
The BIO-POEM study will compare structured biological optimization with standard post-POEM care in patients with objectively confirmed pathological reflux after POEM. The intervention includes reflux-oriented dietary counseling, micronutrient assessment and correction, Helicobacter pylori testing and eradication when indicated, lifestyle optimization, and structured review and tapering of PPI/PCAB therapy.
The study includes two components:
A randomized controlled trial enrolling post-POEM patients with objectively confirmed reflux.
A parallel prospective observational registry enrolling symptomatic post-POEM patients who are unable to undergo reflux testing or who remain symptomatic despite low acid exposure.
The primary objective is to determine whether structured biological optimization reduces GERD symptom burden at 12 months compared with standard care. Secondary objectives include evaluation of dyspepsia symptoms, nutritional recovery, quality of life, reduction in PPI dependence, and exploratory assessment of gut microbiome changes.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Telangana
-
Hyderabad、Telangana、インド、500032
- Asian Institute of Gastroenterology
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria for RCT
- Above criteria plus AET> 6% on pH impedance monitoring.
- Adults aged 18-70 years.
- Patients who stopped PPI/PCABs atleast 4 weeks prior to enrolment (to avoid false negative h.pylori test)
- Prior POEM performed between 6 months and 5 years before enrolment at AIG hospitals.
- Willingness to comply with lifestyle and nutritional interventions.
- Ability to provide written informed consent.
Inclusion Criteria for Observational Registry
- Adults aged 18-70 years.
- Prior POEM performed between 6 months and 5 years before enrolment, at AIG hospitals.
- Clinically significant GERD symptoms after POEM. GERD-HRQL score ≥10, or
- reflux symptoms occurring ≥3 times per week, or
- current use of PPI/PCAB therapy for reflux symptom control
- reflux esophagitis on endoscopy.
- Unable to undergo ambulatory reflux monitoring due to logistical reasons, .
- Ability to provide written informed consent.
Exclusion criteria:
- Prior oesophageal surgery other than POEM.
- Severe comorbidities limiting life expectancy (<2 years).
- Pregnancy or lactation.
- Active gastrointestinal malignancy.
- Contraindication to PPI therapy.
- Inability to provide informed consent or comply with follow-up.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Structured Biological Optimization
Participants in this arm will receive a structured, protocol-driven biological optimization program in addition to standard post-POEM follow-up.
The intervention includes reflux-oriented dietary counseling, lifestyle modification, micronutrient assessment and correction (including vitamin D, B12, iron, calcium, and pre-albumin where deficient), Helicobacter pylori testing and eradication where indicated, and a structured, stepwise de-escalation of proton pump inhibitor (PPI) or potassium-competitive acid blocker (PCAB) therapy based on clinical response and physician assessment.
|
A structured, protocol-driven multimodal intervention designed to optimize post-POEM recovery in patients with achalasia cardia.
The intervention includes individualized reflux-oriented dietary counseling (meal timing, portion control, and trigger food modification), lifestyle optimization (sleep hygiene, weight management, and physical activity guidance), systematic evaluation and correction of micronutrient deficiencies (including vitamin D, vitamin B12, iron, calcium, magnesium, and pre-albumin where indicated), Helicobacter pylori testing with eradication therapy when positive, and a structured, stepwise protocol for proton pump inhibitor (PPI) or potassium-competitive acid blocker (PCAB) de-escalation guided by symptoms and clinical assessment.
The intervention is delivered as a standardized care pathway integrated into routine post-POEM follow-up.
他の名前：
|
|
アクティブコンパレータ：Standard Post-POEM Care
Participants in this arm will receive routine post-POEM care as practiced at the study center.
Management will be symptom-driven and may include proton pump inhibitor (PPI) or PCAB therapy as clinically indicated.
No structured dietary, micronutrient, or deprescribing protocol will be applied beyond standard clinical practice.
Follow-up assessments and outcome evaluations will be performed in the same manner as the intervention arm.
|
A structured, protocol-driven multimodal intervention designed to optimize post-POEM recovery in patients with achalasia cardia.
The intervention includes individualized reflux-oriented dietary counseling (meal timing, portion control, and trigger food modification), lifestyle optimization (sleep hygiene, weight management, and physical activity guidance), systematic evaluation and correction of micronutrient deficiencies (including vitamin D, vitamin B12, iron, calcium, magnesium, and pre-albumin where indicated), Helicobacter pylori testing with eradication therapy when positive, and a structured, stepwise protocol for proton pump inhibitor (PPI) or potassium-competitive acid blocker (PCAB) de-escalation guided by symptoms and clinical assessment.
The intervention is delivered as a standardized care pathway integrated into routine post-POEM follow-up.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Score From Baseline to 12 Months
時間枠：Baseline and 12 months
|
The primary outcome is the change in Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score from baseline to 12 months after randomization in post-POEM patients with objectively confirmed pathological reflux. The GERD-HRQL questionnaire is a validated reflux-specific symptom assessment scale with total scores ranging from 0 to 50, where higher scores indicate worse reflux symptoms and poorer reflux-related quality of life. |
Baseline and 12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Successfully Discontinuing Proton Pump Inhibitor (PPI) or Potassium-Competitive Acid Blocker (PCAB) Therapy by 12 Months
時間枠：6 months and 12 months
|
Proportion of participants successfully discontinuing proton pump inhibitor (PPI) or potassium-competitive acid blocker (PCAB) therapy by 12 months after initiation of study intervention.
|
6 months and 12 months
|
|
Change in Leeds Dyspepsia Questionnaire Score From Baseline to 6 and 12 Months
時間枠：Baseline, 6 months, and 12 months
|
Change in dyspepsia symptom severity assessed using the Leeds Dyspepsia Questionnaire. Higher scores indicate worse dyspepsia symptoms. |
Baseline, 6 months, and 12 months
|
|
Change in Serum Vitamin D Levels From Baseline to 6 Months
時間枠：Baseline and 6 months
|
Change in serum vitamin D levels measured in ng/mL.
|
Baseline and 6 months
|
|
Change in Serum Calcium Levels
時間枠：Baseline and 6 months
|
Change in serum calcium levels measured in mg/dL.
|
Baseline and 6 months
|
|
Change in Serum Iron Levels
時間枠：Baseline and 6 months
|
Change in serum iron levels measured in µg/dL.
|
Baseline and 6 months
|
|
Change in Serum Vitamin B12 Levels
時間枠：Baseline and 6 months
|
Change in serum vitamin B12 levels measured in pg/mL.
|
Baseline and 6 months
|
|
Change in Serum Pre-albumin Levels
時間枠：Baseline and 6 months
|
Change in serum pre-albumin levels measured in mg/dL.
|
Baseline and 6 months
|
|
Change in SF-36 Quality of Life Scores From Baseline to 6 and 12 Months
時間枠：Baseline, 6 months, and 12 months
|
Change in health-related quality of life assessed using the 36-Item Short Form Survey (SF-36). SF-36 scores range from 0 to 100, with higher scores indicating better quality of life. |
Baseline, 6 months, and 12 months
|
協力者と研究者
捜査官
- 主任研究者：Mohan Kumar Ramchandani, MD,DM、Asian Institute of Gastroenterology
出版物と役立つリンク
一般刊行物
- Singh AP, Singla N, Budhwani E, Januszewicz W, Memon SF, Inavolu P, Nabi Z, Jagtap N, Kalapala R, Lakhtakia S, Darisetty S, Reddy DN, Ramchandani M. Defining "true acid reflux" after peroral endoscopic myotomy for achalasia: a prospective cohort study. Gastrointest Endosc. 2024 Feb;99(2):166-173.e3. doi: 10.1016/j.gie.2023.08.008. Epub 2023 Aug 19.
- Nabi Z, Inavolu P, Duvvuru NR. Prediction, prevention and management of gastroesophageal reflux after per-oral endoscopic myotomy: An update. World J Gastroenterol. 2024 Mar 7;30(9):1096-1107. doi: 10.3748/wjg.v30.i9.1096.
- Samarasam I, Joel RK, Pulimood AB. Gastroesophageal reflux following per-oral endoscopic myotomy: Can we improve outcomes? World J Gastroenterol. 2024 Jun 14;30(22):2834-2838. doi: 10.3748/wjg.v30.i22.2834.
- Nabi Z, Basha J, Inavolu P, Goud R, Veligatla V, Tummuru SP, Cheripelli N, Arutla M, Ramchandani M, Darisetty S, Nageshwar Reddy D. Comprehensive analysis of nutritional parameters in patients with idiopathic achalasia: A prospective study in India. Indian J Gastroenterol. 2025 Feb;44(1):57-63. doi: 10.1007/s12664-024-01664-5. Epub 2024 Aug 19.
- Hazrah P. Reflux after peroral endoscopic myotomy: The dilemma and the options. World J Gastroenterol. 2025 Feb 14;31(6):100510. doi: 10.3748/wjg.v31.i6.100510.
- Bapaye A, Yewale R, Shah J, Bale R A, Ansari J, Borkar M, Bapaye H, Pujari R, Gadhikar H. Long-term (3-year) composite gastroesophageal reflux outcomes of peroral endoscopic myotomy with or without concomitant endoscopic fundoplication in matched cohorts of achalasia. Gastrointest Endosc. 2026 Feb;103(2):241-252. doi: 10.1016/j.gie.2025.04.029. Epub 2025 Apr 25.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。